On Thursday, Shares of The Home Depot, Inc. (NYSE:HD), gained 1.60% to $110.04.
The Home Depot, declared that it will hold its First Quarter Earnings Conference Call on Tuesday, May 19, at 9 a.m. ET.
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, in addition to provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me, and professional customers.
Shares of Mattel, Inc. (NASDAQ:MAT), declined -1.36% to $26.83, during its last trading session.
Mattel, declared the appointment of Joseph B. Johnson as Senior Vice President and Corporate Controller, effective right away.
Mr. Johnson, age 52, joins Mattel from Chiquita Brands International, Inc., a leading global marketer and distributor of food products, where he served as Vice President, Chief Accounting Officer & Treasurer. Formerly, Mr. Johnson held a number of leadership roles with Resolute Forest Products, an international wood and paper products company, counting Senior Vice President, Finance and Chief Accounting Officer, Vice President and Corporate Controller and Director of Financial Reporting. Earlier in his career, Mr. Johnson spent nearly 14 years at Ernst & Young LLP. A certified public accountant, Mr. Johnson holds a bachelor’s degree in business administration with an emphasis in accounting from the University of North Florida.
Mr. Johnson succeeds Scott Topham, who has elected to retire from Mattel.
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman.
At the end of Thursday’s trade, Shares of W&T Offshore Inc. (NYSE:WTI), lost -7.43% to $5.73.
W&T Offshore, stated its first quarter 2015 operations and financial results, and 2015 production and expense guidance. Some of the key items comprise:
- Production for the first quarter of 2015 averaged about 49,000 Boe per day (4.4 million Boe in total for the quarter), 53% of which was oil and liquids. Oil production raised 9.4% for the first quarter of 2015 contrast to the first quarter of 2014 while natural gas production reduced 2.1%. Its average quarterly realized sales price was $43.04 per barrel for oil, $16.81 per barrel for natural gas liquids (“NGLs”) and $3.01 per thousand cubic feet (“Mcf”) for natural gas. On a combined basis our average realized sales price was $28.70 per Boe.
- Revenues for the first quarter of 2015 were $127.9 million, 70% of which was from oil and NGLs.
- Continued deepwater development remains on plan at “Big Bend”, “Dantzler”, “Medusa”, and Ewing Banks 910.
- In April 2015 the company amended our existing revolving bank credit facility and modified certain covenants to enhance the Company’s financial flexibility. The borrowing base under the bank credit facility is now $600 million.
- On May 5, 2015, the company declared the pricing and marketing of a $300.0 million five-year second-lien term loan bearing interest at an annual rate of 9.0%.
W&T Offshore, Inc., an independent oil and natural gas producer, together with its auxiliaries, engages in the acquisition, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas.
Finally, Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), ended its last trade with -0.23% loss, and closed at $8.75.
ARIAD Pharmaceuticals, stated financial results for the first quarter of 2015, counting revenue from sales of Iclusig® (ponatinib). The Company also offered an update on corporate developments.
2015 First Quarter Financial Results
- Net product revenues from sales of Iclusig were $23.9 million for the quarter ended March 31, 2015, an enhance of 12% as compared to the fourth quarter of 2014. Net product revenues for the first quarter comprise Iclusig revenues of $18.7 million in the U.S. and $5.2 million in Europe. U.S. sales of Iclusig raised 10% from the fourth quarter of 2014 to the first quarter of 2015, and European sales raised 18%, net of the impact of changes in foreign exchange rates for the first quarter.
- In the quarter ended March 31, 2015, we transitioned to the sell-in method for recognition of product revenues in the U.S., resulting in a one-time addition to revenue of about $1.2 million for the first quarter.
- Shipments of Iclusig to patients in France were $1.9 million for the first quarter of 2015. Cumulative total shipments in France, taking into account the effects of foreign exchange, totaled $18.3 million through March 31, 2015. We will record revenue related to cumulative shipments in France upon completion of pricing and reimbursement negotiations in France, net of any amounts that will be refunded to the French health authorities as a result of such negotiations, which we anticipate will be accomplished in mid-2015.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
